PARG Inhibitor PDD00017272 Small Molecule (Tool Compound)

…of which only a subset are inhibited by the PARP inhibitors, no close homologues of PARG exist. This provides an attractive target for drug discovery, given the cell’s apparent reliance…

Contributors

Inventor Institute
Allan Jordan Cancer Research UK, Manchester Institute
SKU: 154171
Product description: Exploiting the DNA damage response for cancer therapy relies on the fact that rapidly proliferating cancer cells have higher incidences of DNA damage, defective DNA repair pathways, genomic instability, or a combination of these facets. 1-3 Poly(ADP-ribosylation) is a post-translational modification that plays an important role in the repair of damaged sections of DNA.4-6 Poly(ADP-ribose) polymerases (PARPs), in particular PARP1, signal the presence of DNA damage and facilitate DNA repair. Upon DNA damage, PARP1 binds to single-strand break (SSB) sites and autoribosylates using NAD+ as a substrate to form poly(ADP-ribose) (PAR) chains. These PAR chains serve to recruit DNA repair proteins, such as XRCC1, to the site of DNA damage. Poly(ADP-ribose) glycohydrolase (PARG) systematically degrades the ADPribose polymers on the PARP enzyme, which is essential for DNA repair to occur; however, the precise order of events in this catalytic cycle is still unknown. Inhibiting PARG leads to the persistence of PAR chains, with predicted consequences on NAD recycling, PARP recycling, and SSB repair. Although PARP inhibitors have received much attention as cancer therapies, with olaparib approved by the FDA, the dearth of selective, cell-permeable small molecule PARG inhibitors has hampered assessment of the therapeutic potential of targeting PARG in human cancer. Additionally, while there are 17 known PARP family members, of which only a subset are inhibited by the PARP inhibitors, no close homologues of PARG exist. This provides an attractive target for drug discovery, given the cell’s apparent reliance on this single enzyme in nuclear DNA damage repair.
Alternate name: Compound 34f, EP323273
Cat. #: 154171
Tool sub type: Inhibitor
Research Fields: Cancer;Genetics
Purpose: Inhibitor
Primary target: Poly(ADP-ribose) Glycohydrolase (PARG)
Shipping conditions: Dry Ice
References:

J. Med. Chem.2018612310767-10792

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.